MUROMACHI CHEMICALS INC. Logo

MUROMACHI CHEMICALS INC.

A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.

4885 | T

Overview

Corporate Details

ISIN(s):
JP3914800002
LEI:
Country:
Japan
Address:
大牟田市新勝立町一丁目38番5
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Muromachi Chemicals Inc. is a diversified manufacturer operating across four core business segments. The Pharmaceutical division produces and sells medical products and active pharmaceutical ingredients (APIs). The Chemical business specializes in high-performance, customized liquid treatment systems for various applications, including environmental solutions. The Consumer Healthcare division manufactures and markets health foods. Additionally, the Functional Materials segment supports customer development with a broad range of standard and custom-made products for diverse markets. Founded in 1917, the company leverages its long-standing expertise to develop and provide innovative solutions that contribute to health and society.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-26 03:41
Registration Form
確認書
Japanese 8.7 KB
2025-08-26 03:40
Registration Form
有価証券報告書-第79期(2024/06/01-2025/05/31)
Japanese 1020.4 KB
2025-01-14 08:01
Report Publication Announcement
確認書
Japanese 8.7 KB
2025-01-14 08:00
Interim Report
半期報告書-第79期(2024/06/01-2025/05/31)
Japanese 214.1 KB
2024-09-04 03:00
Post-Annual General Meeting Information
臨時報告書
Japanese 27.6 KB
2024-08-28 08:34
Regulatory News Service
内部統制報告書-第78期(2023/06/01-2024/05/31)
Japanese 22.8 KB
2024-08-28 08:32
Annual Report
有価証券報告書-第78期(2023/06/01-2024/05/31)
Japanese 986.7 KB
2024-08-28 08:32
Regulatory News Service
確認書
Japanese 8.7 KB
2024-04-12 09:01
Report Publication Announcement
確認書
Japanese 8.7 KB
2024-04-12 09:01
Quarterly Report
四半期報告書-第78期第3四半期(2023/12/01-2024/02/29)
Japanese 178.7 KB
2024-01-12 08:02
Quarterly Report
四半期報告書-第78期第2四半期(2023/09/01-2023/11/30)
Japanese 213.9 KB
2024-01-12 08:02
Report Publication Announcement
確認書
Japanese 8.7 KB
2023-10-13 09:02
Regulatory News Service
確認書
Japanese 8.7 KB
2023-10-13 09:01
Quarterly Report
四半期報告書-第78期第1四半期(2023/06/01-2023/08/31)
Japanese 182.3 KB
2023-08-29 03:35
Post-Annual General Meeting Information
臨時報告書
Japanese 24.0 KB

Automate Your Workflow. Get a real-time feed of all MUROMACHI CHEMICALS INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MUROMACHI CHEMICALS INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MUROMACHI CHEMICALS INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.